Why Two Imaging Centers Changed Their Contrast Medium

With so many different gadolinium-based contrast agents (GBCAs) here is a manuscript of real-world case histories of healthcare systems who have successfully made the switch from their existing GBCA formulary to the first clinically available ionic, macrocyclic GBCA, DOTAREMĀ® (gadoterate meglumine) Injection.

Disclaimer: The white paper sponsor may contact you but will not share the information you submit in the form.